Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected first-line metastatic non-small cell lung carcinoma

被引：5
|
作者：
Majem, M. [1 ]
Felip, E. [2 ]
Doger, B. [3 ]
Akay, M. [4 ]
Carcereny, E. [5 ]
Clay, T. [6 ]
Krebs, M. G. [7 ]
Peguero, J. [8 ]
Triebel, F. [9 ]
机构：
[1] Hosp Santa Creu & Sant Pau, Med Oncol Dept, Barcelona, Spain
[2] Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain
[3] Fdn Jimenez Diaz, START Madrid FJD, Madrid, Spain
[4] Univ Coll London Hosp, Oncol Dept, London, England
[5] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol Badalona, Oncol Dept, Badalona, Spain
[6] St John God Subiaco Hosp, Oncol Dept, Perth, WA, Australia
[7] Christie NHS Fdn Trust, Div Canc Sci, Manchester, Lancs, England
[8] Oncol Consultants, Oncol Dept, Houston, TX USA
[9] Immutep SAS Immutep, Immunol, Orsay, France
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1580
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1266P
引用
收藏
页码：S818 / S818
页数：1
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS AND BUDGET IMPACT OF PEMBROLIZUMAB MONOTHERAPY AS THE FIRST-LINE TREATMENT FOR METASTATIC NON-SMALL CELL LUNG CANCER PATIENTS WITH PD-L1 ≥ 50% IN THAILAND
    Thamlikitkul, L.
    Leelavanich, D.
    Krairojananan, W.
    Chamnanreong, R.
    Sriuranpong, V
    VALUE IN HEALTH, 2024, 27 (06) : S68 - S69
  • [32] Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression
    Aguilar, E. J.
    Ricciuti, B.
    Gainor, J. F.
    Kehl, K. L.
    Kravets, S.
    Dahlberg, S.
    Nishino, M.
    Sholl, L. M.
    Adeni, A.
    Subegdjo, S.
    Khosrowjerdi, S.
    Peterson, R. M.
    Digumarthy, S.
    Liu, C.
    Sauter, J.
    Rizvi, H.
    Arbour, K. C.
    Carter, B. W.
    Heymach, J. V.
    Altan, M.
    Hellmann, M. D.
    Awad, M. M.
    ANNALS OF ONCOLOGY, 2019, 30 (10) : 1653 - 1659
  • [33] Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China
    Liao, Weiting
    Huang, Jiaxing
    Hutton, David
    Li, Qiu
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (04) : 344 - 349
  • [34] LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes
    He, Yayi
    Yu, Hui
    Rozeboom, Leslie
    Rivard, Christopher J.
    Ellison, Kim
    Dziadziuszko, Rafal
    Suda, Kenichi
    Ren, Shengxiang
    Wu, Chunyan
    Hou, Likun
    Zhou, Caicun
    Hirsch, Fred R.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (05) : 814 - 823
  • [35] FIRST-LINE PEMBROLIZUMAB IN PD-L1 POSITIVE NON-SMALL CELL LUNG CANCER: A COST-EFFECTIVENESS ANALYSIS FROM A UK HEALTHCARE PERSPECTIVE
    Hu, X.
    Goldman, D. P.
    VALUE IN HEALTH, 2017, 20 (09) : A399 - A399
  • [36] Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab
    Banna, Giuseppe Luigi
    Signorelli, Diego
    Metro, Giulio
    Galetta, Domenico
    Toma, Alessandro De
    Cantale, Ornella
    Banini, Marco
    Friedlaender, Alex
    Pizzutillo, Pamela
    Garassino, Marina Chiara
    Addeo, Alfredo
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (04) : 1533 - +
  • [37] Combination of paclitaxel and a LAG-3 fusion protein (eftilagimod alpha), as a first- line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): Final results from the run-in phase of a placebo-controlled randomized phase II
    Duhoux, Francois P.
    Jager, Agnes
    Dirix, Luc Yves
    Huizing, Manon Thirza
    Jerusalem, Guy Heinrich Maria
    Vuylsteke, Peter
    De Cuypere, Eveline
    Breiner, Doris
    Mueller, Christian
    Brignone, Chrystelle
    Triebel, Frederic
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] Cost-Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels
    Weng, Xiuhua
    Luo, Shaohong
    Lin, Shen
    Zhong, Lixian
    Li, Meiyue
    Xin, Rao
    Huang, Pinfang
    Xu, Xiongwei
    ONCOLOGY RESEARCH, 2020, 28 (02) : 117 - 125
  • [39] Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study
    Kawachi, Hayato
    Tamiya, Motohiro
    Tamiya, Akihiro
    Ishii, Seigo
    Hirano, Katsuya
    Matsumoto, Hirotaka
    Fukuda, Yasushi
    Yokoyama, Toshihide
    Kominami, Ryota
    Fujimoto, Daichi
    Hosoya, Kazutaka
    Suzuki, Hidekazu
    Hirashima, Tomonori
    Kanazu, Masaki
    Sawa, Nobuhiko
    Uchida, Junji
    Morita, Mitsunori
    Makio, Takeshi
    Hara, Satoshi
    Kumagai, Toru
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (01) : 211 - 218
  • [40] FEASIBILITY OF EFTILAGIMOD ALPHA (SOLUBLE LAG-3 PROTEIN) COMBINED WITH STANDARD-OF-CARETHERAPY IN ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) ADENOCARCINOMAS. INITIAL RESULTS FROM INSIGHT-003
    Atmaca, Akin
    Mueller, Daniel W.
    Habibzade, Timursah
    Schaaf, Marina
    Klagges, Jorge
    Eickhoff, Regina
    Jaeger, Elke
    Al-Batran, Salah-Eddin
    Goetze, Thorsten O.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A604 - A604
12345